Once again PEGS Europe showcases current
advances with bispecifics with presentations across several tracks from
academic and industry pioneers in the field.
• Advancing Bispecifics
and Combination Therapy to the Clinic presents clinical updates from Abbvie,
Macrogenics, and Molecular Partners. Data-rich late preclinical studies to be
presented by Xencor and Roche.
• We provide an exciting
update from Amgen Research on bispecific T-cell engagers (BiTEs) and include
current developments on bispecifics for retargeting and reprogramming of T
cells from Chugai, Numab, Pfizer, Xencor, Macrogenics and Roche Innovation
• We feature bispecifics
that target checkpoint regulation from NovImmune, Roche, Macrogenics, Xencor
and Shanghai Hengrui Pharmaceuticals.
• We present fascinating
data on Duokines capable of amplifying immune responses, on functional aspects
of Antigen- and Fc-Dependent IgG Hexamers that potentiate CDC and more, on
synergistic effects with an EGFR x cMet bispecific antibody, and advantages
seen with antibody mixtures.
• We focus on the big
challenges for the industry such as identifying target pairs, enhancing
potency, improving avidity, overcoming safety and pharmacology liabilities, and
DON'T MISS the Breakout Round Tables for
• Preclinical and Clinical
Challenges for Bispecific Redirected T Cell Killing
• Understanding the Pros
and Cons of the Myriad Bi- and Multi-specific Antibody Formats
Considerations for Bispecifics
DON'T MISS the short courses:
• Cancer Immunotherapy
• Engineering of